By Vincent Caradec, Co-Founder and CEO, Healthi Life Somewhere, this week, someone is booking a flight in the hope that...
Regenerative medicine is entering a defining phase as stem-cell research moves beyond laboratory discoveries towards cli...
Jiahui International Hospital has launched Jiahui International Cell Therapy Centre (JICC), building on landmark CAR-T c...
Artificial intelligence is reshaping biologics development by enabling faster antibody selection, early identification o...
Cell Therapies Pty Ltd (CTPL) and S2N.Bio have commenced technology transfer of S2N’s cell therapy candidate for A...
Andelyn Biosciences (“Andelyn”), a leading US-based patient-focused cell and gene therapy Contract Developme...
South Korea-based GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, and...
Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences,...
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies ...
The Association for the Advancement of Blood & Biotherapies (AABB) has published a special supplemental issue of its...
IASO Biotechnology has received US Food and Drug Administration clearance for the Investigational New Drug application o...
Switzerland based Tenthpin Management Consultants, a global leader in management and technology consulting for Life Scie...
Teijin Limited, Teijin Regenet Co., Ltd., and Shinshu University Hospital have entered into a joint research agreement r...
As cell therapies advance towards greater clinical sophistication and commercial scale, the focus is shifting fr...
Andelyn Biosciences has partnered with Queen’s University to develop and manufacture AAV9-GM2, an investigational ...
Researchers from A*STAR have identified spatial differences in early brain development that could help explain why autis...
In conversation with BioSpectrum Asia, Laurie Masiello and John Masiello, Co-Founders of Predictive Monitor, explore how...
Australia is rapidly evolving beyond its reputation as a destination for early-stage clinical trials to build a more com...
IASO Biotechnology has completed its acquisition of Singapore-based MediSix Therapeutics, expanding its international ce...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
The next generation of cell and gene therapies is pushing manufacturing beyond the limits of conventiona...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
As gene therapy moves from scientific promise towards a new phase of commercial maturity, manufacturing has emerged as o...
As cell and gene therapies progress from promising research to commercial reality, manufacturing has emerged as ...
The rapid expansion of in vivo gene therapy is reshaping expectations for viral vector manufacturing, placing greater em...
